Histogenics

Histogenics was acquired by Ocugen, (Nasdaq: OCGN) on September 27, 2019.

Histogenics (Nasdaq: HSGX) is a leader in personalized restorative cell therapies (RCT) for active living. Our first investigational product candidate, NeoCart® is a proprietary RCT that rebuilds a patient’s own knee cartilage, treating pain at the source and potentially preventing progression to osteoarthritis (OA).

Website: https://goo.gl/Qtusgh
Industry : Biotechnology
Company size : 51-200 employees
Headquarters : Waltham, MA
Type : Public Company
Founded : 2000
Specialties : Regenerative Medicine, Tissue Engineering, Musculoskeletal and Orthopaedics, and Cartilage Regeneration and Repair
Location : 300 Executive Boulevard Ossining, NY 10562
Willful Violator: No  
H1B Dependent: Yes  
Economic Sector: n.a.
NAICS Industry: Medical and Diagnostic Laboratories; Scientific Research and Development Services

Contacts:

Sungkyu KIM | Vice President | 300 Executive Blvd Ossining, NY | 914-762-0300 | Sungkyu@histogenetics.com

Sungyu KIM | Vice President | 300 Executive Boulevard Ossining, NY | 914-762-0300 | Sungkyu@histogenetics.com

Nezih Cereb | President | 300 Executive Blvd Ossining, NY | 914-762-0300 | Nezih@histogenetics.com

LCA filing for H1B Visa Jobs
2020 : 12
2019 : 14
2018 : 11
2017 : 19
2016 : 21
2015 : 22
2014 : 15
2013 : 18
2012 : 10
2011 : 9

LC filing for green card under PERM
2020 : 0
2019 : 1
2018 : 1
2017 : 6
2016 : 16
2015 : 1
2014 : 0
2013 : 0
2012 : 0
2011 : 2